Completed PHASE3 INTERVENTIONAL 2-arm NCT00870493

Aliskiren for Immunoglobulin A (IgA) Nephropathy

The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study

Sponsor: Chinese University of Hong Kong

Conditions IgA Nephropathy

Interventions Aliskiren Placebo

Updated 5 times since 2017 Last updated: Dec 3, 2012 Started: Apr 30, 2009 Primary completion: Mar 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on IgA Nephropathy, this trial is completed. The trial is conducted by Chinese University of Hong Kong and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese University of Hong Kong

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shatin, Hong Kong